Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
MOMA Therapeutics
MOMA Therapeutics
Eli Lilly and Company
Eli Lilly and Company
Kivu Bioscience Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
National Cancer Institute (NCI)
Conjupro Biotherapeutics, Inc.
Eli Lilly and Company
National Cancer Institute (NCI)
GlaxoSmithKline
Institut Paoli-Calmettes
Orano Med LLC
Stanford University
M.D. Anderson Cancer Center
The Methodist Hospital Research Institute
Tomsk National Research Medical Center of the Russian Academy of Sciences
Alterome Therapeutics, Inc.
Baptist Health South Florida
ViroMissile, Inc.
IntoCell, Inc
Tizona Therapeutics, Inc
Clasp Therapeutics, Inc.
Angiex, Inc.
NiKang Therapeutics, Inc.
MacroGenics
Nanjing Sanhome Pharmaceutical, Co., Ltd.
General Oncology, Inc.
Artios Pharma Ltd
University of Washington
OncoNano Medicine, Inc.
National Institutes of Health Clinical Center (CC)
Abramson Cancer Center at Penn Medicine
Dartmouth-Hitchcock Medical Center
National Cancer Institute (NCI)
Hummingbird Bioscience
M.D. Anderson Cancer Center
University of Kansas Medical Center
Sichuan Baili Pharmaceutical Co., Ltd.
NiKang Therapeutics, Inc.
Hunan Cancer Hospital
Circle Pharma
Nurix Therapeutics, Inc.
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd
Memgen, Inc.
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd